In this article, we discuss the 5 best pharmaceutical stocks to buy according to billionaire Joseph Edelman. If you want to read our detailed analysis of Edelman’s history and hedge fund performance, go directly to the 10 Best Pharmaceutical Stocks to Buy According to Billionaire Joseph Edelman.
5. Agile Therapeutics, Inc. (NASDAQ: AGRX)
Edelman’s Stake Value: $33,113,000
Percentage of Joseph Edelman’s 13F Portfolio: 0.41%
Number of Hedge Fund Holders: 6
Agile Therapeutics, Inc. (NASDAQ: AGRX) an American women’s healthcare company, which experiments, develops, and commercializes prescription contraceptive products for women. The company was incorporated in 1997 and stands fifth on the list of 10 best pharmaceutical stocks to buy according to billionaire Joseph Edelman. Agile Therapeutics currently has a $118.27 million market capitalization.
On May 4, Agile Therapeutics, Inc. (NASDAQ: AGRX) declared quarterly earnings per share of -$0.20 beating the estimates by $0.01. In April, the stock was rated as “Outperform” at RBC Capital, where the price target was set at $8.00.
Perceptive Advisors holds 15.92 million shares of the company, worth $33.11 million. In the first quarter of 2021, 6 hedge funds in the database of Insider Monkey held stakes worth $35.25 million in Agile Therapeutics, Inc. (NASDAQ: AGRX), down from 8 the preceding quarter worth $48.21 million.
4. VYNE Therapeutics Inc. (NASDAQ: VYNE)
Edelman’s Stake Value: $46,368,000
Percentage of Joseph Edelman’s 13F Portfolio: 0.58%
Number of Hedge Fund Holders: 9
VYNE Therapeutics Inc. (NASDAQ: VYNE) is a pharmaceutical company, which focuses on developing and commercializing various medicines for dermatology. The company was founded in 2003 and is placed fourth on the list of 10 best pharmaceutical stocks to buy according to billionaire Joseph Edelman. VYNE currently has a $184.48 million market capitalization.
On May 6, VYNE Therapeutics Inc. (NASDAQ: VYNE) declared its earnings per share of -$0.37, beating market predictions by $0.03. On March 1, VYNE Therapeutics shares gained 5% after announcing its development plans for FMX114 for the treatment of atopic dermatitis.
The stock is a new arrival on Joseph Edelman’s portfolio, as his hedge fund bought about 6.77 million shares of the company, worth $46.37 million. In the first quarter of 2021, 9 hedge funds in Insider Monkey’s database held stakes in VYNE Therapeutics Inc. (NASDAQ: VYNE), compared to 11 funds in the fourth quarter of 2020.
3. Verrica Pharmaceuticals Inc. (NASDAQ: VRCA)
Edelman’s Stake Value: $54,698,000
Percentage of Joseph Edelman’s 13F Portfolio: 0.68%
Number of Hedge Fund Holders: 7
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) is an American dermatology medicine company. The company was incorporated in 2013 and stands third on the list of 10 best pharmaceutical stocks to buy according to billionaire Joseph Edelman. Verrica currently has a $318.5 million market capitalization.
On May 7, Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) announced its Q1 2021 earnings per share of -$0.04 beating market predictions by $0.32. On May 13, RBC Capital rated the stock as “Outperform,” and set a price target at $19.00.
Perceptive Advisors increased his hold in Verrica by 6% in the first quarter of 2021, ending the period with $54.70 million worth of the company’s shares. In the first quarter of 2021, 7 hedge funds in the database of Insider Monkey held stakes worth $80.28 million in Verrica Pharmaceuticals Inc. (NASDAQ: VRCA), up from 4 the preceding quarter worth $61.03 million.
2. Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
Edelman’s Stake Value: $188,682,000
Percentage of Joseph Edelman’s 13F Portfolio: 2.37%
Number of Hedge Fund Holders: 48
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) is a bioprocessing company that focuses on the diagnosis, development, and marketing of medicines. It was founded in 2005 and is placed second on the list of 10 best pharmaceutical stocks to buy according to billionaire Joseph Edelman. Horizon stock has returned 65.72% to investors over the course of the past 12 months.
On June 21, Arrowhead Pharmaceuticals and Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) collaborated for ARO-XDH. It is a possible treatment for people with severe gout conditions. Arrowhead will receive as much as $700 million under the deal. On June 23, the company reported positive results from its AROHSD1001, that will treat patients with liver diseases. While on March 22, Morgan Stanley analyst David Risinger initiated coverage on Horizon Therapeutics with an “Overweight” rating and set the price target at $103.00.
Perceptive Advisors owns 2.05 million shares worth $188.68 million in the first quarter of 2021. Out of the hedge funds being tracked by Insider Monkey, VenBio Select Advisor is a leading shareholder in Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) with 9 million shares worth $828.36 million.
Carillon Tower Advisers, in their Q1 2021 investor letter, mentioned Horizon Therapeutics Public Limited Company (NASDAQ: HZNP). Here is what the fund said:
“Horizon Therapeutics is a biopharmaceutical company whose primary focus is research, development, and marketing of late-stage pharmaceutical products. After experiencing some unfortunate manufacturing hiccups in the later stages of 2020 for its key product Tepezza, which is used in the treatment of thyroid eye disease, the company recently received positive news that should relieve their supply issues going forward. With manufacturing of Tepezza back online after being forced to halt due to Operation Warp Speed’s COVID-19 vaccine production orders, Horizon expects patient treatments to resume in mid-April.”
1. Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
Edelman’s Stake Value: $23,185,000
Percentage of Joseph Edelman’s 13F Portfolio: 0.29%
Number of Hedge Fund Holders: 15
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) is a pharma company, which develops and commercializes medicines to control pain. The company was founded in 2002 and is ranked first on the list of 10 best pharmaceutical stocks to buy according to billionaire Joseph Edelman. Collegium shares have gained about 33.15% in value over the last 12 months.
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) posted earnings for the first quarter of 2021 on May 6, reporting earnings per share of $0.41, beating market predictions by $0.11. The revenue for the first three months of 2021 was $87.72 million, up 14.7% YoY, beating the estimates by $6.09 million. The company raised its FY 2021 adjusted EBITDA guidance to $170.0 to $180.0 million from $160.0 to $170.0 million.
As of Q1 2021, 15 hedge funds in Insider Monkey’s database of 887 funds held stakes in Collegium Pharmaceutical, Inc. (NASDAQ: COLL), compared to 20 funds in Q4 2020.
You can also take a peek at 10 Best Pharmaceutical Stocks to Buy According to Cathie Wood and Top 15 Pharmaceutical Companies With Highest R&D Spending.
